GlassScriptPhysician profile
Robert F Glover
NPI 1164466298
$6,182.02
in general payments reported to CMS, 2019-2025
26 companies · $682 in 2025
The $682 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $569 · 2021: $1,079 · 2022: $1,420 · 2023: $1,001 · 2024: $738 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,421.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,286.13 | 2019-2023 | Xarelto |
| Edwards Lifesciences Corporation | $617.93 | 2021-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $557.21 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $533.92 | 2021-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.07 | 2019-2025 | Jardiance |
| Pfizer INC. | $465.83 | 2022-2025 | |
| Boston Scientific Corporation | $365.65 | 2019-2025 | General - Therapies, Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $309.15 | 2021-2022 | |
| Esperion Therapeutics, INC. | $200.96 | 2020-2021 | |
| Irhythm Technologies, INC. | $200.32 | 2020-2024 | Zio Xt Patch, Zio Monitor |
| Amgen INC. | $185.83 | 2022-2025 | Repatha, Repatha |
| Kiniksa Pharmaceuticals International, Plc | $149.88 | 2024 | Arcalyst |
| Intuitive Surgical, INC. | $124.99 | 2025 | |
| Kestra Medical Technology Services, INC. | $108.97 | 2022-2023 | Assure Wcd |
| Merck Sharp & Dohme LLC | $104.10 | 2021-2025 | Verquvo, Capvaxive |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $92.89 | 2022-2023 | |
| Sk Life Science, INC. | $86.80 | 2022-2025 | |
| Novo Nordisk INC | $69.51 | 2023 | Ozempic, Rybelsus |
| Bridgebio Pharma, INC. | $53.40 | 2025 | Attruby |
| Inspire Medical Systems, INC. | $37.83 | 2023 | Inspire |
| Regeneron Healthcare Solutions, INC. | $28.08 | 2023 | Evkeeza |
| Abbott Laboratories | $24.26 | 2023 | Amplatzer Amulet |
| Xeris Pharmaceuticals, INC. | $23.55 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.23 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $17.17 | 2025 | |
| Biotronik INC. | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Glover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.